Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B StudyBenzinga • 04/21/21
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis BBusiness Wire • 04/21/21
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19GlobeNewsWire • 04/15/21
Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?The Motley Fool • 04/10/21
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host CellsGlobeNewsWire • 04/08/21
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/21
Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 InfectionBenzinga • 04/05/21
Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California VariantGlobeNewsWire • 04/05/21
Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 PatientsBenzinga • 03/29/21
Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7Market Watch • 03/29/21
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19PRNewsWire • 03/29/21
GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 DrugBenzinga • 03/26/21
GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatmentMarket Watch • 03/26/21
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19GlobeNewsWire • 03/26/21
Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?Zacks Investment Research • 03/12/21
Vir Biotechnology spikes 36% after it says its COVID-19 treatment reduced hospitalizations and deaths in high-risk patientsBusiness Insider • 03/11/21
Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New TestInvestors Business Daily • 03/11/21